Streetbeat News

Price Targets

DENN

Citigroup analyst Jon Tower has maintained a Neutral rating on Denny's (NASDAQ:DENN) and lowered the price target from $13 to $9.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:03 pm

DG

Citigroup analyst Paul Lejuez has maintained a Neutral rating on Dollar General (NYSE:DG) and lowered the price target from $146 to $115.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:02 pm

PODD

Leerink Partners analyst Mike Kratky has initiated coverage on Insulet (NASDAQ:PODD) with an Outperform rating and a price target of $184.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:02 pm

DISH

Citigroup analyst Michael Rollins has maintained a Neutral rating on DISH Network (NASDAQ:DISH) and lowered the price target from $9 to $6.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:01 pm

LPRO

Open Lending (NASDAQ:LPRO) has received 5 analyst ratings in the last quarter, with 1 being bullish and 4 somewhat bullish. The average 12-month price target for the stock has increased by 16.36% from $11.00 to $12.8.

Portfolio Pulse from Benzinga Insights

October 16, 2023 | 4:00 pm

VCEL

Leerink Partners analyst Mike Kratky has initiated coverage on Vericel (NASDAQ:VCEL) with an Outperform rating and a price target of $42.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:00 pm

EXLS

Citigroup analyst Ashwin Shirvaikar has maintained a Neutral rating on ExlService Holdings (NASDAQ:EXLS) and lowered the price target from $32.4 to $32.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 4:00 pm

ISRG

Leerink Partners analyst Mike Kratky has initiated coverage on Intuitive Surgical (NASDAQ:ISRG) with an Outperform rating and a price target of $342.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 3:59 pm

OTEX

Citigroup analyst Steve Enders has maintained a Neutral rating on Open Text (NASDAQ:OTEX) and lowered the price target from $44 to $38.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 3:58 pm

TNDM

Leerink Partners analyst Mike Kratky initiates coverage on Tandem Diabetes Care with a Market Perform rating and announces a price target of $21.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2023 | 3:57 pm